IMMUNOGLOBULIN-G SEROPREVALENCE AGAINST SARS-COV-2 AND ASSOCIATED RISK FACTORS IN LAHORE, PAKISTAN; A POPULATION-BASED SURVEY

Main Article Content

Shazia Muneer
Muhammad Hassan Mushtaq
Mamoona Chaudhry
Amjad Khan
Sana Ullah Iqbal
Muhammad Nawaz
Furqan Awan
Nadeem Ahmed

Keywords

SARS-CoV-2, COVID-19, Seroprevalence, Antibodies, asymptomatic carriers

Abstract

SARS-CoV-2, a novel beta corona virus, is considered responsible for recent COVID-19 pandemic. Due to high proportions of asymptomatic cases, it is difficult to determine the full scope of virus circulation or its true infection ratio. To get beyond these limitations and understand infection rates at the population level, serology testing is a crucial component. A cross-sectional investigation was carried out. Individuals from various towns were identified for recruitment into the study, which were not diagnosed previously as COVID-19 positive by Polymerase Chain reaction and not vaccinated yet.  384 individuals with >18 years of age were screened for SARS-CoV-2 specific Immunoglobulin G antibodies. A total of 384 people were tested for SARS-COV-2 IgG, and 178 of them tested positive, representing an overall prevalence of 46%. Prevalence detected was 32.4% in 18-30 years age group, 50.8% among 31-50 year and 44.4% in 51-70 years age group. Among genders, Prevalence detected was 47% among male and 45.3% from females. Chi square and binary logistic regression was applied to see the significance and association of the study variables. The 33 participants contacted with positive family member and 22 of them tested positive for IgG, with the odds of having neutralizing antibodies (OR 3.390, 95% CI 1.365-8.418). In addition to SARS-CoV-2 infection, the population's antibody status was associated with protection. The seroprevalence statistics show that Lahore's population lacks herd immunity. If a new strain enters the community, the likelihood of a serious outbreak in the future increases.

Abstract 176 | Pdf Downloads 40

References

1. 1. Zhao L, Jha BK, Wu A, Elliott R, Ziebuhr J, Gorbalenya AE, et al. Antagonism of the interferon-induced OAS-RNase L pathway by murine coronavirus ns2 protein is required for virus replication and liver pathology. Cell host & microbe. 2012;11(6):607-16.
2. 2. Singh AK, Misra A. Impact of COVID-19 and comorbidities on health and economics: Focus on developing countries and India. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(6):1625-30.
3. 3. Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID‐19) implicate special control measures. Journal of medical virology. 2020;92(6):568-76.
4. 4. Gao Z, Xu Y, Sun C, Wang X, Guo Y, Qiu S, et al. A systematic review of asymptomatic infections with COVID-19. Journal of Microbiology, Immunology and Infection. 2021;54(1):12-6.
5. 5. Moghadas SM, Fitzpatrick MC, Sah P, Pandey A, Shoukat A, Singer BH, et al. The implications of silent transmission for the control of COVID-19 outbreaks. Proceedings of the National Academy of Sciences. 2020;117(30):17513-5.
6. 6. Organization WH. Considerations for public health and social measures in the workplace in the context of COVID-19. 2020.
7. 7. Huang L, Zhang X, Zhang X, Wei Z, Zhang L, Xu J, et al. Rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COVID-19: A prospective contact-tracing study. Journal of Infection. 2020;80(6):e1-e13.
8. 8. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. New England journal of medicine. 2020;382(10):970-1.
9. 9. Toulis P. Estimation of COVID-19 prevalence from serology tests: A partial identification approach. Journal of Econometrics. 2021;220(1):193-213.
10. 10. Zaidi S, Rizwan F, Riaz Q, Siddiqui A, Khawaja S, Imam M, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in residents of Karachi—challenges in acquiring herd immunity for COVID 19. Journal of Public Health. 2021;43(1):3-8.
11. 11. Poustchi H, Darvishian M, Mohammadi Z, Shayanrad A, Delavari A, Bahadorimonfared A, et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. The Lancet Infectious Diseases. 2021;21(4):473-81.
12. 12. Megasari NLA, Utsumi T, Yamani LN, Gunawan E, Furukawa K, Nishimura M, et al. Seroepidemiological study of SARS-CoV-2 infection in East Java, Indonesia. Plos one. 2021;16(5):e0251234.
13. 13. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of 2019 novel coronavirus infection in China. MedRxiv. 2020.
14. 14. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-based differences in susceptibility to Current Biology SARS-CoV infection. J Immunol. 2017;198(10):4046-53.
15. 15. Cheng H-Y, Jian S-W, Liu D-P, Ng T-C, Huang W-T, Lin H-HJm. High transmissibility of COVID-19 near symptom onset. 2020.
16. 16. Abbas S, Raza A, Iftikhar A, Khan A, Khan S, Yusuf MA. Seroprevalence of SARS-CoV-2 antibodies among health care personnel at a health care system in Pakistan. Asia Pacific Journal of Public Health. 2021;33(5):632-4.
17. 17. Kenyon C. Widespread use of face masks in public may slow the spread of SARS CoV-2: An ecological study. medRxiv. 2020.
18. 18. Mutambudzi M, Niedwiedz C, Macdonald EB, Leyland A, Mair F, Anderson J, et al. Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants. Occupational and Environmental Medicine. 2021;78(5):307-14.
19. 19. Führer A, Frese T, Karch A, Mau W, Meyer G, Richter M, et al. COVID-19: Wissensstand, Risikowahrnehmung und Umgang mit der Pandemie. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen. 2020;153:32-8.
20. 20. Peak CM, Kahn R, Grad YH, Childs LM, Li R, Lipsitch M, et al. Individual quarantine versus active monitoring of contacts for the mitigation of COVID-19: a modelling study. The Lancet Infectious Diseases. 2020;20(9):1025-33.

Most read articles by the same author(s)